advertisement
Value in Health 13
Showing records 1 to 13 | Display all abstracts in Value in Health24652 A comprehensive systematic review of the psychometric properties of VFQ-25 in glaucoma
Ejzykowicz F; Gwadry-Sridhar F
Value in Health 2009; 12: A526
24648 One-day cross sectional study in Glaucoma
Nordmann JP; Baudouin C; Bron A; Denis P; Renard JP; Rouland JF; Sellem E; Estphan M; Kosa M
Value in Health 2009; 12: A458
24658 Conjunctival hyperaemia associated with the fixed combinations of latanoprost/timolol and bimatoprost/ timolol in the treatment of ocular hypertension or glaucoma
Vinuesa MJ; Vinuesa I; Diaz S; Martin I; Soto J; Fernandez-Arias I
Value in Health 2009; 12: A453
24647 Treatment persistency of xalatan-xalacom, lumigan ganfort and travatan-duotrav: An analysis conducted on the United-Kingdom general practitioner research database
Berdeaux G; Lafuma A; Robert J
Value in Health 2009; 12: A452
24653 Adherence to antiglaucoma drug treatment in newly treated patients
Moisan J; Fredette MJ; Duchesne T; Sirois C; Gregoire JP
Value in Health 2009; 12: A457-A458
24655 A french economic model comparing cost-effectiveness of duotrav and xalacom in Glaucoma
Lafuma A; Laurendeau C; Berdeaux G
Value in Health 2009; 12: A455
24650 Interventional procedures in glaucoma: resources and costs in five european countries
Lafuma A; Verboven Y; Darba J; Brueggenjuergen B; Gylee E; Berto P
Value in Health 2009; 12: A460
24659 Cost effectiveness analysis of tafluprost compared with latanoprost on the treatment of primary open angle glaucoma in South Korea
Song HJ; Kang SH; Heo JH; Lee EK
Value in Health 2009; 12: A456-A457
24649 The application of discrete event simulation to quantitative risk benefit analysis
Maguire A; Douglas I; Blak BT
Value in Health 2009; 12: A453
24657 Costs of glaucoma in Denmark
Olsen J; Berdeaux G
Value in Health 2009; 12: A455
24656 An economic analysis to evaluate anti-glaucoma pharmacotherapy
Bhowmik D; Sansgiry SS
Value in Health 2009; 12: A75
24651 How and why automated medical databases should be used to create background occurrences for drug outcomes and safety studies: Glaucoma in thin (UK)
Maguire A; Blak BT
Value in Health 2009; 12: A489
24654 Micro-costing vs gross-costing in the estimation of costs for the pharmoeconomic evaluation of glaucoma in Korea
Kang SH; Lee EK
Value in Health 2009; 12: A234
